February 2022 "We are proud to announce the success of our IPO! Thank you to our shareholders, both historical and new, for their trust. The €25 million fundraising gives us the means to achieve our ambitions: to become a leading player in the field of brain diseases! #IPO #biotech #innovation #traitements #addiction #cannabis #Trisomie21 #Downsyndrome" Read more at the source #DrGPCR #GPCR #IndustryNews

cardiovascular diseases, renal diseases, autoimmune diseases such as systemic sclerosis or systemic lupus

Neurosterix launches with $63M to Advance Allosteric Modulator Therapeutics for Neurological Disorders Aelis

Andreas Glück , Martina Guggeis , Alexander Ossysek , Andre Küller , Derk Frank , Christoph Lange , Jan Rupp

project, licensed to AstraZeneca (Saphnelo™ Anifrolumab) that has just received FDA approval for systemic lupus